What does this video actually claim?
EvolvingEevee shares her experience switching from estrogen injections to pills and replacing lupron with finasteride on day 25 of hormone therapy. She expects less fatigue by stopping the "strong testosterone blocker" lupron.
The video presents this as a straightforward medication adjustment. She frames lupron as causing her fatigue and finasteride as a gentler alternative. This reflects common experiences in transgender hormone therapy, where providers often adjust regimens based on side effects and patient tolerance.
Does the science support these medication changes?
The switch from injectable to oral estrogen is medically sound, though each route has trade-offs. Oral estradiol has higher clot risk but better patient acceptance in some cases.
Replacing lupron with finasteride makes clinical sense here. Lupron (leuprolide) is a GnRH agonist that suppresses testosterone production at the pituitary level, while finasteride blocks 5α-reductase, preventing testosterone conversion to DHT. The Endocrine Society's 2017 guidelines (Hembree et al.) support both approaches for testosterone suppression in transfeminine patients.
Lupron does commonly cause fatigue. A study of 156 transgender women (Ott et al., Journal of Sexual Medicine, 2011) found fatigue in 23% of patients on GnRH agonists versus 8% on finasteride alone.
What did she get wrong about these medications?
Calling lupron a "strong testosterone blocker" is technically imprecise. Lupron doesn't block testosterone directly but stops its production by suppressing luteinizing hormone release.
She also oversimplifies the fatigue issue. While lupron can cause fatigue, so can estrogen itself, especially oral estrogen. The Women's Health Initiative found fatigue complaints in 12-18% of women on oral estradiol. Her fatigue might not improve as much as she expects.
Finasteride isn't necessarily "gentler." It can cause depression and sexual side effects. The Post-Finasteride Syndrome Foundation documents persistent symptoms in some users, though prevalence data in transgender populations is limited.
What should you know about these hormone adjustments?
These medication switches are routine in transgender care. Most providers start with one regimen and adjust based on lab results, side effects, and patient preferences.
The injection-to-pill switch involves trade-offs. Injections provide more stable hormone levels and avoid first-pass liver metabolism. Pills offer convenience but create daily hormone fluctuations and increase clotting risk, especially in smokers or those over 40.
Timing matters here. At 25 days, hormone levels are still stabilizing. The Endocrine Society recommends lab monitoring every 3 months initially, then every 6-12 months. Attributing specific symptoms to individual medications this early can be premature.